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Chronic infection with hepatitis B virus (HBV), a 
hepatotropic DNA virus, is a major cause of liver 
disease worldwide. More than 350 million people 
are persistently infected and at risk of developing 
chronic liver infl  ammation resulting in liver cir-
rhosis and hepatocellular carcinoma. The World 
Health Organization estimates that at least 1 mil-
lion deaths each year are directly attributable to 
HBV-related liver disease. An increasing propor-
tion of the chronic disease seen in many countries 
is due to the development of viral variants lacking 
the expression of “e” antigen but associated with 
active viral replication and liver disease, termed e 
antigen negative chronic hepatitis B (eAg-CHB; 
reference 1). Patients with eAg-CHB are prone 
to recurrent, spontaneous “hepatic fl  ares,” char-
acterized by large, unexplained fl  uctuations  in 
liver infl  ammation and a propensity to progress 
rapidly to severe liver fi  brosis (2). These hepatic 
flares provide a window of opportunity to 
study mechanisms involved in dynamic altera-
tions in viral load and liver infl  ammation over a 
condensed timeframe. Because HBV is non-
cytopathic, liver damage is thought to be immune 
mediated, but the molecular pathways leading to 
hepatocyte death in human HBV infection are 
not well understood. There is a pressing need to 
dissect the ways in which diff  erent components 
of the immune response contribute to liver 
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Hepatitis B virus (HBV) causes chronic infection in more than 350 million people world-
wide. It replicates in hepatocytes but is non-cytopathic; liver damage is thought to be 
immune mediated. Here, we investigated the role of innate immune responses in mediating 
liver damage in patients with chronic HBV infection. Longitudinal analysis revealed a 
temporal correlation between fl  ares of liver infl  ammation and fl  uctuations in interleukin 
(IL)-8, interferon (IFN)-𝗂, and natural killer (NK) cell expression of tumor necrosis factor–
related apoptosis-inducing ligand (TRAIL) directly ex vivo. A cross-sectional study con-
fi  rmed these fi  ndings in patients with HBV-related liver infl  ammation compared with 
healthy carriers. Activated, TRAIL-expressing NK cells were further enriched in the liver of 
patients with chronic HBV infection, while their hepatocytes expressed increased levels of a 
TRAIL death–inducing receptor. IFN-𝗂 concentrations found in patients were capable of 
activating NK cells to induce TRAIL-mediated hepatocyte apoptosis in vitro. The pathogenic 
potential of this pathway could be further enhanced by the ability of the IFN-𝗂/IL-8 
combination to dysregulate the balance of death-inducing and regulatory TRAIL receptors 
expressed on hepatocytes. We conclude that NK cells may contribute to liver infl  ammation 
by TRAIL-mediated death of hepatocytes and demonstrate that this non-antigen–specifi  c 
mechanism can be switched on by cytokines produced during active HBV infection.
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  disease in HBV infection. This will allow the rational devel-
opment of immunotherapeutic strategies that enhance viral 
control while limiting or blocking liver infl  ammation.
Immune-mediated liver damage in patients with HBV in-
fection has conventionally been attributed to cytolytic killing 
of infected hepatocytes by virus-specifi  c CD8 T cells. How-
ever, this assumption was challenged by previous work dem-
onstrating the presence of activated HBV-specifi  c CD8 T cells 
at high frequencies in the livers of patients controlling HBV 
infection without any evidence of liver infl  ammation. Instead, 
the distinguishing feature between patients with or without 
HBV-related chronic liver disease was the presence of a large, 
non-antigen–specifi  c lymphocytic infi  ltrate in the livers of the 
former group (3). The mechanisms resulting in the recruit-
ment and activation of this nonspecifi  c infl  ammatory infi  ltrate 
have been explored in the transgenic mouse model of HBV. 
In this model, it was possible to reduce the severity of liver 
damage by inhibiting the nonspecifi  c cellular infi  ltrate (4, 5), 
reinforcing the concept that liver infl  ammation initiated by 
virus-specifi  c CD8 is amplifi  ed by other lymphocytes (6).
One of the largest constituents of the lymphocytic infi  l-
trate in HBV transgenic mice is NK cells (NK1.1+CD3−), 
with a 10–12-fold increase in their numbers in the infl  am-
matory infi  ltrate compared with baseline (4, 5). NK cells 
(CD3−CD56+) are likewise a major component of the cellu-
lar infi  ltrate in the human liver, comprising 30–40% of total 
intrahepatic lymphocytes (7). An early rise in circulating NK 
cells has been documented in the incubation phase of HBV 
infection, suggesting that they may contribute to the initial 
viral containment in this setting (8). The antiviral and patho-
genic potential of NK cells in patients with chronic HBV in-
fection remain to be addressed.
The mechanism through which NK cells mediate antivi-
ral cytotoxicity appears to be organ dependent (9). NK cyto-
toxicity through perforin/granzyme is now considered to be 
of less relevance in the liver environment, where the target 
hepatocytes are relatively resistant to lysis through this path-
way (9, 10). Receptor-mediated cell death through ligand–
receptor pairs belonging to the TNF superfamily is likely to 
play a more important role in liver damage (11, 12). One 
such pathway is mediated through TNF-related apoptosis-
inducing ligand (TRAIL; reference 13) expressed on infi  l-
trating lymphocytes interacting with TRAIL death–inducing 
receptors (TRAIL-R1 and TRAIL-R2; reference 14) on 
hepatocytes. This has been shown to be a critical mechanism 
of liver damage in vivo in Listeria and concanavalin A–
induced hepatitis in mice (15). An essential role for NK cells 
in hepatic TRAIL-mediated apoptosis was highlighted in 
the setting of the surveillance of tumor metastases (16). 
Normal human hepatocytes have also been shown to be 
sensitive to TRAIL-mediated apoptosis (17, 18), and it has 
been suggested that susceptibility to this pathway may be 
increased during viral hepatitis (19, 20). We therefore hy-
pothesized that NK-expressed TRAIL may play a role in 
non-antigen–specifi  c mediation of liver damage in chronic 
HBV infection.
NK cell eff  ector function is a result of the balance of signals 
through their activatory and inhibitory receptors, a balance 
that is infl  uenced by the local cytokine milieu. Furthermore, 
NK cells can be directly activated to antiviral activity by cer-
tain cytokines, with IFN-α promoting cytotoxicity (21) and 
TRAIL expression (22), and IL-12 favoring IFN-γ produc-
tion (21). IFN-α production characterizes the early stages of 
acute viral infections, but it is unclear whether its release can 
also be triggered by fl  uctuations in viral load occurring on the 
background of the persistent high level antigenic stimulation 
found in chronic HBV infection. The downstream eff  ects of 
any IFN-α produced may be attenuated in antigen-activated 
cells (23, 24) or modifi  ed by an increase in other cytokines, 
such as IL-1β (25) and IL-8 (26, 27).
To understand the cytokine milieu infl  uencing NK cell 
activity, we quantifi  ed  IFN-α and several other key pro-
infl   ammatory and immunoregulatory cytokines in patients 
with chronic HBV infection. We took advantage of a cohort 
of well-characterized patients with eAg-CHB sampled repeat-
edly before, during, and after multiple hepatic fl  ares to corre-
late sensitive measurements of their serum cytokine levels 
with changes in liver infl  ammation. We observed large fl  uc-
tuations in serum IFN-α and IL-8 concentrations in associa-
tion with the hepatic fl  ares. Increases in circulating IFN-α 
and IL-8 in CHB patients with liver infl  ammation were ac-
companied by an increase in NK cell activation and surface 
TRAIL expression measured directly ex vivo. We then ex-
plored the mechanisms underlying these ex vivo observa-
tions, which could explain the resultant liver damage. We 
established that the concentrations of IFN-α and IL-8 pro-
duced in vivo promoted the TRAIL pathway of NK cell 
killing, acting on both the ligand and the receptors. We con-
fi  rmed that, in the presence of this combination of cytokines, 
NK cells from patients with chronic HBV infection became 
capable of TRAIL-mediated killing of hepatocytes.
RESULTS
Large fl  uctuations in circulating levels of IFN-𝗂 and IL-8 
during fl  ares of liver disease in chronic HBV infection
Patients with eAg-CHB are susceptible to spontaneous fl  ares 
of liver infl  ammation associated with rapid changes in viral 
load. These fl  ares provide an opportunity to investigate me-
chanisms of HBV-related liver damage during periods of 
dynamic fl  uctuation that are predictable enough to be cap-
tured upon longitudinal sampling. A cohort of 14 eAg-CHB 
patients that had previously been identifi  ed as likely to un-
dergo recurrent hepatic fl  ares (2) were recruited and studied 
longitudinally. Through frequent sampling, serum was ob-
tained before, during, and after one or multiple fl  ares, defi  ned 
in this study as an abrupt increase in serum alanine transami-
nase (ALT) to more than double the baseline value and more 
than three times the upper limit of normal (<35 IU/L for 
women, <50 IU/L for men). Serum ALT was used as a sur-
rogate marker for liver damage because studies in chimpan-
zees (28) and humans (29) infected with HBV have shown 
that it accurately predicts histological fi  ndings of hepatic JEM VOL. 204, March 19, 2007  669
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infl  ammation. All patients included had a well-characterized 
disease course with clinical monitoring for at least 1 yr and 
between 4 and 10 serial samples available for the study (see 
Table II), usually taken at intervals of 1–2 mo. Using a cyto-
metric bead array (CBA) infl  ammation kit and ELISA tech-
nology, it was possible to quantitate multiple cytokines 
simultaneously from a small volume of serum. The cytokines 
analyzed were IL-8, IL-1β, IL-6, IL-10, TNF, IL-12p70, 
and IFN-α. Of the seven cytokines examined, only IL-8 and 
IFN-α were consistently detected, with peak concentrations 
far in excess of those observed for the other fi  ve cytokines 
in patients and signifi  cantly higher than in healthy controls 
(Table I and Fig. S1, which is available at http://www.jem
.org/cgi/content/full/jem.20061287/DC1). The serum levels 
of these two cytokines were observed to undergo large fl  uctua-
tions, which were recurrent in the cases with multiple fl  ares 
(Fig. 1 a), with patients consistently displaying substantial 
fold changes throughout the fl  aring events assayed (Table II). 
These uniform, large fl  uctuations were not observed with the 
other cytokines measured (Fig. 1 a).
The patients in this cohort had a marked degree of liver 
infl   ammation (indicated as maximum ALT, Table II) and 
high viral load (see maximum viral load, Table II) at the 
height of the fl  are. Changes in serum IFN-α and IL-8 levels 
showed a temporal association with fl  uctuations in ALT and 
HBV-DNA (Fig. 1 b). For the majority of patients (10/14), 
the peak serum level of IL-8 preceded the onset of the fl  are 
of liver infl  ammation (the sample just before the ALT peak) 
Figure 1.  IL-8 and IFN-𝗂 concentrations are elevated in the se-
rum of CHB patients with liver infl  ammation. (a) Circulating concen-
trations of multiple cytokines detected in longitudinal serum samples 
taken from a representative patient (patient 1) assayed by CBA (IL-8, 
IL-1β, IL-6, IL-10, TNF, and IL-12p70) and sandwich ELISA (IFN-α). The 
concentrations of infl  ammatory cytokines were determined by CBA soft-
ware or Prism. (b) Temporal relationship between serum IL-8 and IFN-α 
concentrations and liver infl  ammation (ALT) and viral load (HBV-DNA) in 
4 representative patients of 14 patients assayed. Cross-sectional com-
parison of IL-8 (c) and IFN-α (d) levels quantitated by sandwich ELISA in 
healthy donors, HBV patients with low ALT (ALT < 60 IU/l for the last 
year), and HBV patients with raised ALT (ALT > 60 IU/L at time of sam-
pling). Signifi  cance testing was performed using the Mann-Whitney 
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either simultaneous to or immediately after a sharp increase 
in viral load (Fig. 1 b and Table II). Maximal serum concen-
trations of IFN-α occurred concurrently with the peak of 
liver infl  ammation (Fig. 1 b and Table II; median interval be-
tween IFN-α peak and ALT peak, 0) at a time when IL-8 
levels were declining but still highly elevated compared with 
healthy controls (Fig. 1, a and b).
To establish whether elevated levels of IL-8 and IFN-α 
were restricted to HBV patients with active disease or could 
also be found in the absence of liver infl  ammation, we con-
ducted a large cross-sectional study. Serum IFN-α and IL-8 
concentrations were compared in controls without HBV in-
fection, patients with chronic HBV infection with no evi-
dence of liver infl  ammation (ALT < 60 IU/L at the time of 
sampling and no ALT > 60 IU/L recorded in the preceding 
year), and patients with HBV infection with liver infl  amma-
tion (ALT > 60 IU/L at the time of sampling). HBV patients 
with liver infl  ammation had signifi  cantly raised levels of both 
IL-8 (Fig. 1 c) and IFN-α (Fig. 1 d) compared with the con-
trol groups. In contrast, healthy donors consistently had low 
or undetectable levels of these two cytokines, and patients 
with chronic HBV without evidence of liver infl  ammation 
had no signifi  cant increases in IL-8 and IFN-α compared 
with healthy donors (Fig. 1, c and d). Further analysis of these 
data revealed a similar correlation of raised IL-8 levels and a 
high HBV viral load (not depicted), supporting the original 
observation that fl  uctuations in IL-8 concentrations mirrored 
those of HBV-DNA (Fig. 1 b).
Direct ex vivo correlation between NK cell expression 
of the proapoptotic ligand TRAIL and HBV-related 
liver infl  ammation
A large proportion of IFN-α–activated NK cytotoxicity is 
mediated through the proapoptotic ligand TRAIL (22), re-
cently identifi  ed as a major eff  ector in murine models of liver 
damage (15). Having established that the dominant cytokines 
during fl  ares were IFN-α and IL-8, we investigated if there 
was an associated activation of the NK cell TRAIL pathway. 
Human NK cells have been reported to express little or no 
TRAIL on their surface when freshly isolated from healthy 
donor blood (30–32). However, some NK cell TRAIL is de-
tectable upon permeabilization (30), and they are capable of 
up-regulating it upon activation in culture (31, 32). In con-
trast, CD3−CD56+ NK cells from an eAg-CHB patient with 
recurrent fl  ares were found to have a clear population surface 
costaining with an anti-TRAIL mAb directly ex vivo (Fig. 
2 a). The proportion of NK cells expressing surface TRAIL 
further increased when ALT was raised (Fig. 2 a).
Table I.  IL-8 and IFN-α levels are highly elevated in sera 
from eAg-CHB patients with fl  ares
Median of peak cytokine 
concentration (pg/mL)
CHB patients Healthy controls p-values
IL-8 630 13 <0.0001
IL-1β 79 blq 0.07
IL-6 11 blq 0.08
IL-10 9 1.7 0.04
TNF 4 blq 0.64
IL-12p70 17 2.6 0.1
IFN-α 253 20 0.005
The median value is that of the maximum cytokine concentration obtained from 12 
CHB patients undergoing fl  ares of liver infl  ammation and 14 healthy control donors. 
Signifi  cance testing was performed using the Mann-Whitney U test, with those of 
statistical signifi  cance highlighted in bold. blq, below level of quantifi  cation.
Table II.  IL-8 and IFN-α serum concentrations correlate temporally with hepatic fl  ares
No. 
of samples
Max viral load
(106 copies/mL)
Max ALT
(IU/L)
IL-8 max fold 
changea
Sampling interval between 
ALT peak and IL-8 peakb
IFN-𝗂 max 
fold change
Sampling interval between 
ALT peak and IFN-𝗂 peak
Patient 1 7 975 546 136 −1 152 −3
Patient 2 10 31.4 285 686 0 7 0
Patient 3 7 141 569 237 −2 6.8 −1
Patient 4 8 417 208 417 −21 2 n a
Patient 5 8 16.4 495 40 2 7.2 −5
Patient 6 7 5.67 313 8.2 −17 0
Patient 7 7 1,510 214 29 −12 0 0
Patient 8 5 63.8 201 303 −3 3.7 0
Patient 9 4 21.4 565 11 0 2.4 −1
Patient 10 4 418 880 1.7 −3 3.2 0
Patient 11 5 600 403 5.2 0 2.3 2
Patient 12 5 1,800 614 5.4 −1 1.4 −2
Patient 13 5 19 158 32 0 8.2 1
Patient 14 4 800 196 70 −1 9.5 0
Median 36 −17 0
aThe fold change of IL-8 or IFN-α from baseline levels to the peak of the cytokine fl  uctuation.
bA negative value implies the cytokine peak occurs before the height of the fl  are, and a zero means it coincided with the fl  are. na, data not available.JEM VOL. 204, March 19, 2007  671
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In a subset of fi  ve patients from our longitudinal cohort of 
eAg-CHB patients for whom serial PBMCs were available 
before, during, and after fl  ares, we were able to make a tem-
poral analysis of NK cell activation and TRAIL expression. 
As illustrated for two representative patients in Fig. 2 b, sur-
face TRAIL expression on NK cells showed large variations 
ex vivo concurrent with hepatic fl  ares (Fig. 2 b, top). The 
NK cell expression of CD69, a marker of activation, also cor-
related tightly with the hepatic fl  are, with peak activation co-
inciding with maximal ALT (Fig. 2 b, top) and with elevated 
levels of IL-8 and IFN-α (Table II).
The majority of TRAIL was noted to be on the CD-
56bright subset of NK cells (see representative sample in Fig. 
2 a) rather than the larger CD56dim subset responsible for 
perforin-mediated cytotoxicity (33). The increase in overall 
NK cell TRAIL expression during fl  ares was noted to be due 
to an increase in the percent of the CD56bright subset within 
the NK cells and an increase in the proportion of these 
CD56bright NK cells expressing TRAIL (Fig. 2 b, bottom).
We then compared the level of NK cell surface TRAIL 
expression in our larger cross-sectional cohort of healthy do-
nors and HBV patients with or without liver infl  ammation. 
The percentage of NK cells expressing TRAIL on their sur-
face directly ex vivo was increased more than fourfold in pa-
tients with liver infl  ammation compared with HBV patients 
with normal ALT (P < 0.001) or healthy donors (P < 0.0001; 
Fig. 2 c). Increased TRAIL expression in patients with liver 
infl  ammation compared with patients with no infl  ammation 
was also observed within the CD56bright subset (P < 0.0005; 
not depicted).
Of note, levels of TRAIL expressed on CD3+ T cells 
remained low upon longitudinal and cross-sectional analysis 
of HBV patients, regardless of the degree of liver infl  amma-
tion (not depicted). In addition, levels of T cell proliferation 
to HBV core and surface antigens showed no increase around 
the time of the fl  are in the three patients in whom this param-
eter was examined longitudinally (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20061287/DC1).
These data, showing an in vivo up-regulation of acti-
vated NK cells expressing TRAIL, suggest a role for NK cells 
using this pathway in the pathogenesis of HBV-induced 
liver disease.
Intrahepatic NK cells express high levels of TRAIL 
and are highly activated
Next, we investigated whether the NK cell TRAIL pathway 
could operate in the liver, the site of active HBV replication. 
It is already well established that NK cells are enriched in 
healthy livers compared with the periphery (7). To identify if 
NK cell numbers are likewise increased in the livers of CHB 
patients, intrahepatic mononuclear cells were isolated from 
HBV-infected livers (three with cirrhosis and two with a 
fl  are), and the proportions of CD3+ T cells, CD3−CD56+ 
NK cells, and CD3+CD56+ NKT cells were determined by 
fl  ow cytometry. As shown in Fig. 3 a, both NK and NKT 
cells were enriched in the liver compared with the periphery 
of HBV-infected patients, with CD3−CD56+ NK cells typi-
cally constituting up to 40% of total intrahepatic lymphocytes. 
This is in line with recent data indicating that NK cells con-
stitute 30–40% of intrahepatic lymphocytes in HBV patients 
(as in healthy controls), regardless of viral load, ALT, or 
histology (34).
Figure 2.  Direct ex vivo correlation between NK cell TRAIL expres-
sion and liver infl  ammation in CHB patients. (a) Representative fl  ow 
cytometry dot plot from a CHB patient stained with mAb to CD3, CD56, 
and TRAIL, and gated on CD3− cells. The percentages denote the propor-
tion of freshly isolated CD3−CD56+ NK cells staining with TRAIL. (b) Top: 
PBMCs from patients with eAg-CHB were stained ex vivo, and the per-
centage of NK (CD3−CD56+) -expressing TRAIL upon fl  ow cytometry was 
correlated with ALT. CD69+ NK cells are presented as a percent of total 
lymphocytes. Bottom: The percent of CD56bright NK cells out of total 
CD3−CD56+ NK cells and the percent of those CD56bright NK cells that 
were TRAIL+ was plotted against ALT. (c) Cross-sectional analysis of ex vivo 
surface TRAIL expression on CD3−CD56+ NK cells from healthy donors, 
HBV patients with low ALT (ALT < 60 IU/l for the last year), and HBV 
patients with raised ALT (ALT > 60 IU/L at time of sampling). Signifi  cance 
testing was performed using the Mann-Whitney U test. 672  MECHANISM OF NK CELL-MEDIATED LIVER DISEASE IN CHRONIC HBV | Dunn et al.
When the activation status of these intrahepatic NK cells 
was assessed, a greater proportion of intrahepatic NK cells 
had up-regulated CD69 than peripheral NK cells from the 
same patient (Fig. 3 b). Of note, the most highly activated 
NK cell subset in the liver was the CD56bright subset (Fig. 3 c), 
a subset that was also preferentially enriched in the liver (not 
depicted and reference 32).
A recent study by Ishiyama et al. (32) showed that TRAIL 
was not detectable on NK cells extracted from healthy livers 
at the time of living donor transplantation. In contrast, we 
found that intrahepatic NK cells isolated from these HBV-
infected livers expressed TRAIL directly ex vivo at even 
higher levels than seen in the periphery of the same patients 
(Fig. 3 d). As in the periphery, TRAIL was predominantly 
expressed on the preferentially activated CD56bright NK sub-
set, and intrahepatic CD3+ T cells expressed little TRAIL 
(Fig. 3 e).
To further examine the relationship between intrahepatic 
NK TRAIL levels and liver infl  ammation, we compared fi  ve 
biopsies taken around the time of an ALT fl  are in patients 
with histologically proven eAg-CHB, with two biopsies 
from HBV patients with normal ALT and histology confi  rm-
ing inactive disease. TRAIL+ lymphocytes (presumed to be 
NK cells because these are the only population expressing 
signifi  cant TRAIL in the periphery or liver) were identifi  ed 
in four out of the fi  ve eAg-CHB sections by immunohisto-
chemistry (Fig. 3 f). In contrast, sections from the two pa-
tients with inactive HBV infection resembled reports of 
healthy livers (32), with no TRAIL-expressing lymphocytes 
identifi   able. The results suggest that intrahepatic NK cell 
TRAIL expression correlates with HBV-related liver infl  am-
mation, as noted in the periphery in Fig. 2.
NK cells from patients with chronic HBV infection 
can be activated and induced to express TRAIL by cytokine 
concentrations found during liver infl  ammation
We next sought to explore possible mechanistic links be-
tween our ex vivo fi  ndings of increases in IFN-α, IL-8, and 
NK-expressed TRAIL in patients with raised ALT. These 
two cytokines found in high concentrations during HBV-
related infl  ammation could contribute to liver damage by 
immunomodulatory eff  ects on NK cells and the TRAIL 
pathway. IFN-α is a modulator of NK cell function, but it 
was unclear how this would be aff  ected by IL-8, an inhibitor 
of its antiviral effi   cacy (26, 27). Furthermore, it was possible 
that NK cells could become resistant to IFN-α–  mediated 
modulation after the recurrent stimulation likely in these pa-
tients with longstanding HBV-related infl  ammation. To in-
vestigate this, PBMCs or purifi   ed NK cells from healthy 
volunteers and patients with chronic HBV were incubated in 
vitro for 24 h with IFN-α or IL-8 alone or in combination at 
concentrations observed during hepatic fl  ares. PBMCs or pu-
rifi  ed NK cells showed a substantial increase in the percent-
age of NK cells expressing TRAIL upon incubation with 
IFN-α (Fig. 4 a). IL-8 did not have a direct eff  ect or inhibit 
the ability of IFN-α to up-regulate TRAIL expression. 
Rather than becoming resistant to the eff  ects of IFN-α, 
NK cells from chronically infected HBV patients, including 
patients undergoing fl  ares, up-regulated TRAIL by a similar 
amount to NK cells from healthy donors (Fig. 4 a). HBV pa-
tients with liver infl  ammation therefore achieved a higher 
Figure 3.  Enrichment of NK cell numbers, TRAIL expression, and 
activation in the liver compared with periphery. (a) Mononuclear cells 
from the periphery and liver of a representative CHB patient were stained 
with antibodies to CD3 and CD56, and the proportion of CD3+ T cells, 
CD3+CD56+ NKT cells, and CD3−CD56+ NK cells (highlighted in box) was 
determined by fl  ow cytometry. NK cells (CD3−CD56+) from liver-infi  ltrating 
(IHL) and circulating (PBL) lymphocytes from fi  ve chronically infected 
HBV patients were assessed ex vivo for CD69 expression (b) and TRAIL 
expression (d). p-values were determined by the Mann-Whitney U test. 
(c) Flow cytometry dot plot analysis of a representative CHB patient com-
paring intrahepatic NK cell activation in the CD56bright and CD56dim NK cell 
subsets. (e) A histogram comparing TRAIL expression on the CD56bright and 
CD56dim NK cell subsets and CD3+ T cells isolated from the liver. (f) Paraffi  n-
embedded liver sections taken from seven HBV patients were stained with 
an anti-TRAIL mAb. The boxed area on the left indicates the fi  eld of view 
on the right panel. TRAIL+ cells are stained brown and are highlighted 
with black arrows. Bar, 40 μm.JEM VOL. 204, March 19, 2007  673
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total NK cell TRAIL level after in vitro IFN-α treatment as 
a result of their higher starting expression ex vivo.
NK cells taken from patients with chronic HBV infection 
also maintained the capacity to be activated by IFN-α, with 
equivalent levels of CD69 up-regulation to that seen in NK 
cells from healthy donors and again no inhibition of this ef-
fect by IL-8 (Fig. 4 b). IFN-α induced equivalent levels of 
activation of highly purifi  ed NK cells, indicating a direct ef-
fect of this cytokine (not depicted). Thus, the in vivo obser-
vations of up-regulation of NK cell TRAIL and CD69 
expression were mirrored in vitro using equivalent concen-
trations of cytokines to those circulating in CHB patients 
with liver infl  ammation.
Cytokine-modulated TRAIL receptor expression 
on hepatocytes in HBV infection
In order for TRAIL to induce receptor-mediated cell death, 
it needs to engage with a death domain receptor on the target 
cell (14). Previous studies have suggested minimal protein 
expression of TRAIL death–inducing receptors in healthy 
livers (19, 35). However, mRNA for the death-inducing re-
ceptors TRAIL-R1 and TRAIL-R2 has been isolated from 
human hepatocytes (14, 17), which become susceptible to 
TRAIL-induced apoptosis upon culture (17), suggesting a 
potential for up-regulation. To ascertain whether hepatocytes 
in HBV-infected livers express a death-inducing receptor 
that could engage with the NK-expressed TRAIL, paraffi   n-
embedded liver sections from HBV-infected and control 
livers were stained for TRAIL-R1 and TRAIL-R2. No 
TRAIL-R1 was detected in the HBV-infected or control 
livers (not depicted). However, TRAIL-R2 was expressed 
by hepatocytes in 10 of the 13 HBV-infected liver sections 
stained (from patients with eAg-CHB, with histology show-
ing mild to moderate infl  ammatory infi  ltrates or cirrhosis). 
Immunostaining for TRAIL-R2 was predominantly local-
ized to the surface of hepatocytes (Fig. 5 a) and ranged from 
strong in three patients, moderate in two, and weak in six, 
with no clear correlation with stage of liver disease. How-
ever, TRAIL-R2 was absent in sections from two control 
HBV patients with normal ALT and inactive disease. TRAIL-
R2 staining was detected in a control donor with hepatic 
steatosis but not in the other control liver sections examined, 
three from healthy donors and four from patients with alco-
holic hepatitis (Fig. 5 a).
Figure 4.  Concentrations of IFN-𝗂 observed in patient sera induce 
increased surface TRAIL expression and activation of NK cells iso-
lated from CHB patients. PBMCs from healthy donors (white bars) and 
CHB patients (black bars) were incubated for 24 h in vitro with 1,000 U/ml 
IFN-α, 5 ng/ml IL-8, or IFN-α and IL-8. The effect of this incubation on 
TRAIL expression (a) and NK cell activation (b) was assessed by fl  ow 
cytometry analysis with NK cells identifi  ed as CD3−CD56+. Graphs were 
plotted by subtracting baseline levels of CD69 or TRAIL observed in the 
untreated controls from those observed after cytokine treatment.
Figure 5.  TRAIL receptor expression on hepatocytes in HBV infection. 
(a) Paraffi  n-embedded sections from HBV-infected (left) and healthy 
control (right) livers were stained with an anti–TRAIL-R2 mAb. Membrane-
localized (arrows) and cytoplasmic (*) TRAIL-R2 expression is indicated 
by the brown chromogen reactivity. Bars: top, 40 μm; bottom, 16 μm. 
(b) Mean fl  uorescence intensity of HepG2 TRAIL-R2 levels after IL-8 incu-
bation (10 ng/ml for 24 h) compared with untreated and isotype controls. 
(c) Mean fl  uorescence intensity of HepG2 TRAIL-R4 levels after 1,000 U/ml 
IFN-α for 24 h compared with untreated and isotype controls. These are 
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We hypothesized that IFN-α or IL-8 might partially 
mediate this altered TRAIL-R expression pattern observed 
in HBV-infected infl  amed livers to favor hepatocyte death. 
To investigate this, HepG2 hepatocytes were incubated 
with IL-8 or IFN-α at equivalent concentrations to those 
circulating in patients, and the levels of expression of the 
death-inducing (TRAIL-R1 and TRAIL-R2) and inhibi-
tory (TRAIL-R3 and TRAIL-R4) TRAIL receptors were 
determined by fl  ow cytometry. IL-8 was consistently found 
to induce an approximate doubling in the expression of 
TRAIL-R2 (Fig. 5 b), the death domain receptor observed 
to be up-regulated on hepatocytes of CHB patients (Fig. 5 a). 
Incubation with IL-8 did not alter surface expression of any 
of the other TRAIL receptors (not depicted). IFN-α had no 
eff  ect on the expression of TRAIL-R2 (not depicted) but 
reproducibly and substantially decreased expression of the 
decoy/regulatory receptor TRAIL-R4 (Fig. 5 c). TRAIL-
R4 has recently been shown to form a ligand-independent 
association with TRAIL-R2 to inhibit apoptosis induction 
(36). Collectively, these results suggest that the high con-
centrations of IL-8 and IFN-α can act in combination to 
both increase a death-inducing receptor and reduce an in-
hibitory receptor, thus optimally predisposing hepatocytes to 
TRAIL-mediated cell death.
Cytokines circulating during HBV fl  ares can render 
NK cells capable of killing hepatocytes through 
TRAIL ligand–receptor interactions
To test whether NK cells isolated from HBV patients could 
kill hepatocytes using TRAIL, we used an assay that can di-
rectly measure the degree of receptor-mediated cell death via 
the caspase cascade pathway used by TRAIL. PBMCs from 
patients were incubated with or without IFN-α overnight to 
induce maximal TRAIL expression on the NK cells. At the 
same time, HepG2 hepatoma cells were preincubated with 
or without IL-8 overnight. Activated PBMCs were then 
added to the HepG2 cells, and the degree of HepG2 cell cas-
pase activation was assessed by fl  ow cytometry. When the 
HepG2 cells or PBMCs were not treated with cytokines, 
there was little caspase activation when compared with the 
background HepG2 cell levels (not depicted). Pretreatment 
of the HepG2 cells with IL-8 increased the amount of 
PBMC-mediated caspase activation, which was further in-
creased when the PBMCs were preincubated with IFN-α 
(Fig. 6 a, top).
To confi  rm that this IFN-α–induced caspase activation 
was TRAIL mediated, the HepG2 cells were preincubated 
with a blocking antibody to TRAIL. As can be seen in the 
bottom of Fig. 6 a, when TRAIL was blocked there was a 
Figure 6.  IFN-𝗂–activated NK cells from CHB patients can medi-
ate TRAIL-induced hepatocyte apoptosis. (a) HepG2 cells were incu-
bated for 24 h with or without 10 ng/ml IL-8. Simultaneously, PBMCs 
were incubated for 24 h with or without 1,000 U/ml IFN-α. Top: PBMCs 
were then added to HepG2 at an E/T ratio of 10:1 for 4 h before visualiza-
tion of caspase activation with the fl  uorescein-labeled Z-VAD-fmk and 
detection by fl  ow cytometry, expressed as mean fl  uorescence intensity 
(MFI). Bottom: Experimental procedure as above except for the addition 
of 10 ng/ml of a TRAIL blocking antibody. (b) Representative results of 
  PBMCs from healthy donors, CHB patients with low ALT, and CHB patients 
with high ALT incubated with 1,000 U/ml IFN-α for 24 h and then as-
sessed for caspase activation of IL-8–treated HepG2 as above. (c) Repre-
sentative HepG2 caspase induction by ex vivo PBMCs from high ALT HBV 
patient and reduction upon the addition of TRAIL blocking mAb. (d) Rep-
resentative HepG2 caspase induction upon the addition of PBMCs taken 
directly ex vivo from a healthy donor, CHB patient with low ALT, and CHB 
patient with high ALT. (e) Summary level of HepG2 caspase induction 
using PBMCs directly ex vivo from HBV patients with liver injury (ALT 
high patients, n = 6) compared with PBMCs from controls (HBV patients 
without raised ALT, n = 3; healthy controls, n = 3; P = 0.03, Mann-
Whitney U test).JEM VOL. 204, March 19, 2007  675
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reduction in IFN-α–induced caspase activation compared 
with the non-antibody–treated cells (varying from 50 to 
100% blocking). This suggests that TRAIL plays a major 
role in the IFN-α–induced caspase activation but may not 
be the only mechanism involved. The IFN-α–induced in-
crease in TRAIL-mediated death was maintained using puri-
fi  ed NK cells and abrogated in NK cell–depleted fractions 
(not depicted).
 PBMCs from HBV patients without liver infl  ammation 
or from healthy controls showed less effi   cient initiation of the 
caspase cascade after up-regulation of NK cell TRAIL with 
in vitro IFN-α treatment (Fig. 6 b). There was twice as much 
caspase induction using IFN-α–activated PBMCs from fl  ar-
ing patients (Fig. 6, a and b) as from healthy donors (Fig. 6 b). 
PBMCs taken from patients with HBV-related liver infl  am-
mation were also able to induce apoptosis when added to 
HepG2 directly ex vivo, partially blocked in all cases (mean 
of 40% blocking) upon the addition of a TRAIL-blocking 
mAb (Fig. 6 c). Patients with HBV liver infl  ammation (n = 6), 
showed a mean of 28% caspase induction over background, 
which was signifi  cantly greater than that seen using PBMCs 
from HBV patients with normal ALT or healthy controls 
(n = 6; Fig. 6, d and e).
These experiments confi  rm that, under the infl  uence of 
cytokines induced during HBV fl  ares, NK cells become ca-
pable of inducing death of HepG2 hepatoma cells through 
the TRAIL pathway.
NK cells from HBV patients with fl  ares can initiate 
TRAIL-induced apoptosis of primary human hepatocytes
The HepG2 hepatoma cell line provided a convenient model 
to dissect the mechanisms of activation of this pathway, but it 
was important to confi  rm that primary human hepatocytes 
would also be susceptible to NK TRAIL-mediated apoptosis. 
Hepatocytes were isolated by perfusion of a nondiseased liver 
explant and cultured for 48 h, with IFN-α and IL-8 added 
for the last 24 h to modulate TRAIL receptor expression. 
Viability of hepatocytes without the addition of PBMCs was 
good (>80% in all wells; Fig. 7 a). In contrast, hepatocytes 
incubated with PBMCs from an HBV patient with a fl  are 
who had TRAIL-expressing NK cells directly ex vivo showed 
hepatocyte apoptosis induction (Fig. 7 b). IFN-α–treated 
PBMCs taken from patients expressing NK cell TRAIL dur-
ing an episode of liver infl  ammation were more effi   cient at 
induction of apoptosis of primary human hepatocytes than 
PBMCs from HBV patients without a fl  are or healthy donors 
(P = 0.02, Mann-Whitney U test; Fig. 7 c). In three out of 
four high ALT patients, >30% of the apoptosis induced by 
IFN-α–treated PBMCs could be blocked through TRAIL 
(mean of 28% blocking for the four patients). Induction of 
apoptosis by PBMCs cultured without IFN-α for 24 h was 
less reliably elicited (showing a mean 15% increase over back-
ground levels in patients with liver disease [P = 0.04] and a 
nonsignifi  cant trend to increased levels in this group com-
pared with controls; Fig. 7 c). A larger study using PBMCs 
directly ex vivo will be required to confi  rm diff  erences 
  between patient groups. However, we can conclude that 
PBMCs from HBV patients with liver infl  ammation whose 
NK cells express TRAIL are capable of mediating death of 
primary human hepatocytes.
DISCUSSION
The protracted, unpredictable natural history of the develop-
ment of liver disease in chronic HBV infection makes it 
diffi   cult to sample the immune correlates of liver damage 
longitudinally. Recurrent hepatic fl  ares occurring on a back-
ground of chronic HBV overcome this problem by allowing 
capture of a compressed version of immunopathogenetic 
events associated with rapid changes in liver disease and 
viral load. Previous studies have examined the fl  ares associ-
ated with eAg seroconversion and those found in patients 
undergoing therapy, demonstrating increases in serum IL-12 
(37) and CD4 T cell reactivity (37–39). In this study, we 
Figure 7.  NK cells from CHB patients can mediate TRAIL-induced 
apoptosis in primary human hepatocytes. Primary human hepatocytes 
were cultured for 48 h with the addition of 10 ng/ml IL-8 and 1,000 U/ml 
IFN-α for the last 24 h. Simultaneously, PBMCs from three healthy donors, 
three CHB patients with low ALT, and four CHB patients with high ALT 
were incubated with or without IFN-α for 24 h at 37°C. The hepatocytes 
and PBMCs were incubated together for 18 h at an E/T ratio of 10:1, with 
or without a TRAIL blocking antibody in the IFN-treated wells. The degree 
of apoptosis was determined by in situ DNA end labeling (ISEL) for the 
detection of DNA fragmentation. (a) A representative image of control 
hepatocytes incubated without PBMCs. Bar, 40 μm. (b) A representative 
image of hepatocytes after an 18-h incubation with PBMCs from a CHB 
patient with high ALT. The arrows represent ISEL+ hepatocytes. (c) Sum-
mary data of percentage of ISEL+ hepatocytes using PBMCs from high 
ALT patients (n = 4) versus controls (low ALT patients, n = 3; healthy 
donors, n = 3) without (white bars) or with (black bars) IFN-α treatment 
and with TRAIL blocking of IFN-α–treated wells (hatched bars). Results 
are presented after subtraction of the mean baseline level of hepatocyte 
apoptosis of 14% seen without the addition of PBMCs, and signifi  cance 
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focused initially on the distinct type of fl  are seen in patients 
with late reactivation of their disease, so called eAg-CHB. 
These patients usually have mutations in their basal core pro-
moter region or stop codon resulting in loss of eAg expres-
sion in the face of high viral load and are at particularly high 
risk of progression to fi  brosis and cirrhosis (1, 2). By repeat-
edly sampling a cohort of patients with eAg-CHB, we were 
able to identify raised and highly fl  uctuating levels of IL-8 
and IFN-α during fl  ares. The proportion of NK cells acti-
vated to express CD69 and the apoptosis-inducing TRAIL 
ligand directly ex vivo also fl  uctuated in parallel with the he-
patic fl  ares. A larger cross-sectional study extended the fi  nd-
ing of elevated levels of serum IL-8, IFN-α, and NK cell 
TRAIL to patients with HBV infection with active liver in-
fl  ammation as opposed to healthy HBV carriers or controls. 
TRAIL-expressing NK cells were further enriched and acti-
vated in the liver of HBV patients, contrasting with the lack 
of intrahepatic TRAIL expression ex vivo in healthy controls 
(32). Investigation of the possible mechanistic links between 
the induction of these cytokines and of the NK cell TRAIL 
pathway revealed that IL-8 is capable of up-regulating a 
death-inducing receptor for TRAIL, increased expression of 
which was observed in CHB livers. IFN-α, at concentrations 
circulating during fl  ares, could promote cell death through 
the TRAIL pathway both by inducing ligand expression on 
NK cells and by reducing inhibition by a regulatory receptor 
on hepatocytes. Together, they render NK cells capable of 
killing hepatocytes through TRAIL.
NK cells are highly enriched in the liver of both healthy 
donors and HBV patients, comprising the dominant intrahe-
patic lymphocyte population, yet their role in HBV-related 
liver damage has not been well defi  ned. Here, we present 
data supporting an important contribution of NK cells to 
HBV-related liver damage, showing activation of NK cells in 
parallel with fl  ares of liver infl  ammation and enrichment of 
activated NK cells in the HBV-infected liver. The CD56dim 
subset expresses the majority of NK cell perforin and gran-
zyme, but hepatocytes are relatively resistant to these classical 
cytolytic eff  ector molecules (9, 10). The CD56bright subset of 
NK cells, noted to be selectively enriched in the periphery 
during fl  ares and preferentially enriched and activated in the 
liver, is known for its immunoregulatory capacity, being a 
potent source of cytokines such as IFN-γ (33). In this study, 
we have concentrated on the potential of these CD56bright 
NK cells to mediate liver damage through an alternative cy-
totoxic pathway, using TRAIL to induce receptor-mediated 
hepatocyte death. TRAIL has been shown to be endoge-
nously expressed by a subset of NK cells found in murine 
livers (16), but this is not the case in humans, where both 
peripheral and intrahepatic NK cells show minimal surface 
TRAIL expression in healthy individuals (30–32). However, 
human NK cells have been reported to be capable of up-
  regulating TRAIL expression upon stimulation in vitro with 
IL-2 (31, 32) or IFN-α (22); we demonstrate that NK cells 
retain the capacity to up-regulate TRAIL both in vitro and 
in vivo, despite the years of recurrent infl  ammation seen in 
these patients with chronic HBV infection. The fact that 
NK cell TRAIL is only elevated in those HBV patients 
manifesting liver infl   ammation (in both longitudinal and 
cross-sectional studies) supports a role for this ligand in hepa-
tocyte damage.
The TRAIL pathway was originally proposed to be re-
stricted to transformed cells, and NK-expressed TRAIL pro-
tects against tumors in the intrahepatic environment (16). 
However, recent human studies have highlighted a patho-
genic role for this pathway outside the context of tumors, 
with lymphocytes mediating TRAIL-induced apoptosis of 
atherosclerotic plaques in acute coronary syndrome (40) and 
of CD4 T cells in HIV infection (41). Studies in mouse models 
of liver disease have reinforced the notion of NK-  expressed 
TRAIL inducing damage of nonmalignant tissues in vivo, 
showing TRAIL-dependent death of hepatocytes (15) and 
hepatic stellate cells (42). The susceptibility of human hepa-
tocytes to TRAIL-induced apoptosis has been an area of 
controversy after initial reports of lack of liver toxicity in 
mice and primates treated with soluble TRAIL (43, 44). 
However, membrane-bound TNF-related ligands have greater 
proapoptotic potential and liver toxicity than their soluble 
counterparts (35, 45). Human membrane-bound TRAIL 
does induce hepatocyte apoptosis in mice, resulting in wide-
spread apoptosis, necrosis, and lymphocytic infi  ltration (35), 
compatible with the pathology of chronic HBV hepatitis. 
Furthermore, normal human hepatocytes have the potential 
to express death-inducing receptors for TRAIL and are sus-
ceptible to TRAIL-induced apoptosis in vitro (17, 18). The 
ratio of expression of death-inducing versus regulatory recep-
tors has been shown to provide a means for fi  ne-tuning the 
susceptibility to TRAIL-induced death (36). There is already 
a suggestion that this balance may be tipped in favor of death 
in situations of liver infl  ammation, such as bile acid retention 
(46) and viral hepatitis. Evidence for the latter comes from 
  immunostaining of hepatitis C virus–infected livers (20) and 
Western blotting of total liver extracts from acute HBV-
  mediated liver failure (19). We show by immunostaining that 
expression of a death-inducing TRAIL receptor is up- regulated 
on hepatocytes of patients with CHB. One mechanism of 
modulation may be by the virus itself, based on the in vitro 
observations that the HBV-encoded X antigen up-regulates 
one of the death-inducing receptors (47) and predisposes to 
TRAIL-induced apoptosis through modulation of intracellu-
lar Bax (48). Here, we demonstrate an additional mechanism, 
whereby cytokines produced during an HBV fl  are may act in 
concert to both increase death-inducing and reduce regulatory 
TRAIL receptors to maximize hepatocyte apoptosis. Our data 
have implications for the use of soluble TRAIL in the therapy 
of malignancies, such as hepatocellular carcinoma. They sug-
gest that tumor patients with coincident HBV infection and 
episodes of active liver infl  ammation might be more suscepti-
ble to hepatic toxicity from such a therapeutic approach.
The chemokine ligand–receptor pairs directing the mi-
gration of this large infl  ux of NK cells in to the HBV-
infected liver still need to be dissected and are currently under JEM VOL. 204, March 19, 2007  677
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investigation. IL-8 is well known for its chemotactic func-
tion, and the high concentrations circulating during fl  ares are 
likely to derive from the liver (unpublished data). In the pa-
tients studied here, IL-8 levels typically increased with the 
increase in HBV DNA, in keeping with the reported ability 
of HBV to transactivate the IL-8 gene (49). NK cells have 
been shown to express the high affi   nity IL-8 receptor CXCR1 
and to migrate in response to IL-8 (50). IFNs have also been 
shown to regulate the traffi   cking of NK cells to the liver by 
induction of chemokines such as IFN-γ inducible protein 10 
in HBV transgenic mice (4) and macrophage infl  ammatory 
protein 1α in murine CMV infection (51). We have not 
shown where the IFN-α surges identifi  ed in this study derive 
from, but likely sources are virally infected hepatocyes in ad-
dition to liver-infi  ltrating leukocytes, including plasmacytoid 
dendritic cells. We therefore speculate that IL-8 and IFN-α, 
in addition to activating a pathway of NK-mediated hepato-
cyte damage, may contribute to the chemotaxis of NK cells 
to the HBV liver during episodes of active infl  ammation.
In the transgenic mouse model of HBV infection, NK 
cells have potent antiviral effi   cacy, an eff  ect that is attenuated 
in mice lacking the type I IFN receptor (52). It is likely that 
IFN-α–activated NK cells have a dual role in viral control 
and liver damage in human HBV infection too. TRAIL-
  induced apoptosis of HBV-infected hepatocytes by NK cells 
would eliminate some virally infected cells, a process that 
could contribute to the partial reduction in viral load often 
observed after a fl  are. However, any viral reduction by this 
means would always be at the expense of liver damage and 
would therefore be a hazardous strategy to promote thera-
peutically. In fact, the use of exogenous IFN-α in the treat-
ment of HBV-associated cirrhosis is often limited by its 
tendency to cause a hepatic fl  are, which can be severe enough 
to precipitate hepatic decompensation. It will be important 
to investigate whether such fl  ares on treatment have a similar 
pathogenesis to the naturally occurring fl  ares  investigated 
here; this would open up the potential to block IL-8 or the 
TRAIL pathway to limit the toxicity of IFN-α therapy. The 
recent fi  nding that liver disease induced by the injection of 
activated lymphocytes into the HBV transgenic mouse can 
be abrogated with a TRAIL blocking antibody (48) lends 
support to this therapeutic strategy.
In summary, we demonstrate that patients with chronic 
HBV infection retain the capacity to activate the type I IFN 
system in the setting of dynamic changes in viral load and 
have fl  uctuating levels of IL-8 that may modulate the role of 
IFN-α in liver damage and viral control. We describe a novel 
mechanism of non-antigen–specifi  c liver damage activated 
by these two cytokines in HBV infection and highlight the 
critical role of the large NK infi  ltrate in this process. CD3+ T 
cells express minimal levels of TRAIL in both the periphery 
and liver of these patients, despite the reported ability of 
IFN-α to up-regulate TRAIL on human T cells (53). How-
ever, it is likely that non-antigen–specifi  c T cells contribute 
to liver damage through other pathways, such as Fas/Fas li-
gand (11, 12). The fact that NK-mediated killing of hepato-
cytes was not completely blocked by TRAIL antibodies 
suggests that NK cells may also use additional ligands to me-
diate liver damage. It remains to be seen whether the NK cell 
TRAIL pathway is also switched on during the large fl  are of 
liver infl  ammation seen during eAg seroconversion and in 
acute HBV infection. A further question not addressed by 
this study is what triggers, rather than mediates, these fl  ares. 
The primary event appears to be an increase in HBV DNA, 
suggesting that there may be an escape from virus-specifi  c 
CD8-mediated viral control. Our data support the idea that 
future immunotherapeutic strategies should aim to promote 
noncytolytic antiviral eff  ects, such as those mediated by   virus-
specifi  c CD8, while blocking the type of non-antigen–
specifi  c mechanism of liver damage described here.
MATERIALS AND METHODS
Patients and controls. 72 patients with chronic HBV infection (HBsAg+) 
were recruited with full ethics approval and informed consent, with 11 pa-
tients being HBeAg+ and the remainder HBeAg− and anti-HBeAb+ (mea-
sured by commercial enzyme immunoassay kits; Murex Diagnostics). 
HBV-DNA viral load was quantifi  ed by the Roche Amplicor Monitor Assay 
(Roche Laboratories). The patients were negative for antibodies to hepatitis 
C virus and hepatitis delta virus, and to HIV-1 and HIV-2 (Ortho Diagnos-
tic System; Murex Diagnostics). None of the patients included in the study 
was taking antiviral therapy or immunosuppressive drugs. Sera were ob-
tained and immediately frozen from 53 patients, PBMCs from 46 patients, 
and liver biopsies/explants or paraffi   n-embedded sections from 20 patients. 
A subset of 14 HBeAg− CHB patients was subjected to longitudinal analysis, 
with multiple serum and PBMC samples taken (Table II). Serum samples 
were analyzed in parallel, and PBMCs were analyzed directly ex vivo.
Control samples consisted of sera and PBMCs from 14 and 13 healthy 
donors, respectively, and paraffi   n-embedded liver sections from 4 healthy 
donors and 4 patients with alcoholic hepatitis.
Antibodies and reagents. The antibodies CD3-Cy5.5/PerCP, CD56-
FITC, TRAIL-PE, CD69-APC (BD Biosciences), TRAIL-R1-PE, TRAIL-
R2-PE, TRAIL-R3-PE, TRAIL-R4-PE, and CD56-PE (R&D Systems) 
were used for fl  ow cytometric analyses at the manufacturers’ recommended 
concentrations. The anti-TRAIL antibody for neutralization of bioactivity 
(R&D Systems) was used at a concentration of 10 ng/ml. Recombinant 
human IFN-α2a (rhIFN-α; PBL Biomedical Laboratories) and recombinant 
human IL-8 (rhIL-8; R&D Systems) were used at concentrations stated for 
each experiment.
Determination of serum cytokine concentrations. Serum cytokine 
concentrations were ascertained using the CBA Infl  ammation kit (BD Bio-
sciences) according to the manufacturer’s protocols. In brief, 50 μl of patient 
serum or standard recombinant protein dilutions was added to a mixture of 
capture beads coated with mAb to a panel of cytokines (IL-8, IL-1β, IL-6, 
IL-10, TNF, and IL-12p70) and a PE-conjugated detection reagent. After 
3 h, the capture beads were washed and acquired on a FACSCalibur fl  ow 
cytometer (BD Biosciences). Using the recombinant standards and the BD 
CBA Software provided, cytokine concentrations were quantifi  ed for each 
serum sample. Serum IFN-α was assayed using a standard sandwich ELISA 
kit (PBL Biomedical Laboratories), where 50 μl of patient serum was ana-
lyzed according to the manufacturer’s High Sensitivity protocol.
Ex vivo staining of NK cells. Freshly isolated PBMCs from HBV patients 
and healthy donors, or intrahepatic lymphocytes isolated from HBV patients as 
described previously (3), were incubated for 30 min at 4°C with antibodies 
to CD3, CD56, CD69, and TRAIL. PBMCs were washed twice with PBS 
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FACSCalibur fl  ow cytometer. Isotype-matched control mAbs were used for de-
fi  ning positive population staining with the CD69 and TRAIL-specifi  c mAbs.
Immunohistochemistry of liver samples for TRAIL and TRAIL 
  receptors. Archival paraffi   n blocks from 15 CHB, 4 alcoholic liver disease 
cases, and 4 healthy donors were stained for the expression of TRIAL-R1 and 
TRAIL-R2. Serial sections from seven eAg-CHB patients were stained for ex-
pression of TRAIL. 4-μm sections were cut onto charged slides (Surgipath) and 
heated for 1 h at 60°C. After deparaffi   nizing and rehydration, sections were 
treated in 0.3% H2O2 in water to block endogenous peroxidase activity. Antigen 
retrieval was performed using the ALTER technique as described previously 
(54). After a brief wash in water, sections were placed onto a Sequenza 
(Shandon) and washed in TBS/Tween, pH 7.6. mAbs to TRAIL-R1 (1:100 
dilution; R&D Systems) or TRAIL-R2 (1:50 dilution; R&D Systems) were 
applied for 40 min at room temperature. Sections were washed in TBS/Tween, 
and antibody was detected using Dako Chemate Envision horseradish peroxi-
dase kit (DakoCytomation). Sections were washed in water, counterstained in 
hematoxylin, dehydrated, placed into xylene, and mounted in DPX mountant.
Cytokine-induced NK cell activation and up-regulation of TRAIL 
expression. PBMCs were resuspended in supplemented RPMI 10% FCS, 
plated into a round-bottom 96-well tissue culture plate at 3 × 105 cells/well, 
and incubated with 1,000 U/ml rhIFN-α, 5 ng/ml rhIL-8, or IFN-α and 
IL-8 for 24 h at 37°C. The degree of cytokine-induced NK activation and 
up-regulated TRAIL expression was determined by subtracting baseline 
CD69 or TRAIL expression from that observed after cytokine treatment.
Cytokine-induced changes in TRAIL-R expression on the HepG2 
hepatoma cell line. HepG2 hepatoma cells were trypsinized from a 75-cm2 
fl  ask and plated into a 48-well fl  at-bottom tissue culture plate at 2 × 105 
cells/well. The cells were allowed to adhere for 5 h before the addition of 
10 ng/ml rhIL-8 or 1,000 U/ml rhIFN-α and incubated for 24 h at 37°C. 
The wells were washed twice with PBS and incubated on ice for 45 min 
with 5 mM EDTA. This gentle detachment from the plate prevented the 
loss of surface TRAIL-R expression. The cells were then washed twice with 
PBS plus 1% FCS to remove the EDTA before incubation for 30 min at 4°C 
with mAbs to the four membrane-bound TRAIL receptors and acquisition 
on a FACSCalibur fl  ow cytometer.
NK-expressed TRAIL-mediated apoptosis of HepG2 cell line. HepG2 
cells were trypsinized from a 75-cm3 fl  ask, plated into a 48-well fl  at-bottom 
tissue culture plate at 105 cells/well, and allowed to adhere. Adhered cells 
were incubated with and without 10 ng/ml IL-8 or 1,000 U/ml IFN-α at 
37°C for 24 h. PBMCs (or purifi  ed NK cells or NK-depleted PBMCs) from 
chronic HBV patients were also incubated with and without 1,000 U/ml 
IFN-α at 37°C for 24 h. After this incubation a TRAIL-blocking antibody 
was added to the relevant wells for 1 h before the addition of PBMCs 
to HepG2 wells at a ratio of 10:1 (PBMC/HepG2). After 4 h, the degree of 
caspase activation was determined using the carboxyfl  uorescein-FLICA 
apoptosis detection kit (Serotec) using the manufacturer’s protocol for detec-
tion by fl  ow cytometry.
NK-expressed TRAIL-mediated apoptosis of primary human hepato-
cytes. Primary human hepatocytes were isolated from nondiseased liver 
explant tissue using collagenase perfusion (55), resuspended in Williams E 
medium containing hydrocortisone, insulin, and glutamine, plated into a 
48-well fl  at-bottom culture plate at 105 cells per well, and allowed to adhere 
for 2 h. Medium was replaced, and cells rested for 24 h before stimulation 
for 24 h at 37°C with 10 ng/ml IL-8 and 1,000 U/ml IFN-α. PBMCs from 
CHB or healthy donors were incubated with or without 1,000 U/ml IFN-α 
at 37°C for 24 h. After this time, 10 ng/ml of a TRAIL blocking antibody 
was added to the relevant well for 2 h before PBMCs were added to hepato-
cytes at a ratio of 10:1 (PBMC/hepatocyte) and incubated for a further 18 h 
at 37°C before fi  xing with methanol. The degree of apoptosis was deter-
mined by in situ DNA end labeling (ISEL) for the detection of DNA frag-
mentation (55). In brief, the fi  xed cells were incubated with ISEL mixture 
(TBS, pH 7.6, plus 5 mM MgCl, 10 mM 2-mercaptoethanol, 5 mg/ml bo-
vine serum albumin, 20 units Klenow DNA polymerase [Bioline], 0.01 M of 
nucleotides dATP, dCTP, and dGTP [Invitrogen], and digoxygenin-labeled 
dUTP [Roche Laboratories]) for 1 h at 37°C. The sections were then washed 
with distilled water and incubated with sheep anti-digoxygenin alkaline 
phosphatase–conjugated Fab fragment (1:200 dilution; Roche Laboratories) 
for 1 h at room temperature. After further washing in TBS, pH 7.6, sections 
were incubated with alkaline phophatase substrate for 15 min, counterstained 
with Mayers hematoxylin, and refi  xed in methanol at 4°C.
Induction of apoptosis was quantifi  ed by an independent observer blinded 
to the study design, who counted at least 200 hepatocytes in each well.
Online supplemental material. Fig. S1 shows the individual values and 
means for serum concentrations of cytokines assayed by CBA (IL-8, IL-1β, 
IL-6, IL-10, TNF, and IL-12p70) and sandwich ELISA (IFN-α). Fig. S2 
shows the results of proliferative assays performed at multiple longitudinal 
time points in three CHB patients with fl  ares after 5 d of stimulation with 
HBcAg and HbsAg. Figs. S1 and S2 are available at http://www.jem.org/cgi/
content/full/jem.20061287/DC1.
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